Serum interleukin-5 levels correlate with disease activity of Churg-Strauss syndrome in a patient treated with a leucotriene receptor antagonist, pranlukast, and inhaled corticosteroid
| Autor: | Eiji Sugiyama, Reina Ogawa, H. Taki, Koichiro Shinoda, Kazuyuki Tobe, Shin Ishizawa, Hiroyuki Hounoki |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
medicine.drug_class Immunology Anti-Inflammatory Agents Churg-Strauss Syndrome Severity of Illness Index Pranlukast Rheumatology medicine Immunology and Allergy Humans Anti-Asthmatic Agents Receptor Interleukin 5 Eosinophil cationic protein business.industry Eosinophil Cationic Protein Antagonist Interleukin Receptors Interleukin-2 General Medicine Receptor antagonist Androstadienes Treatment Outcome Chromones Corticosteroid Fluticasone Leukotriene Antagonists Drug Therapy Combination Interleukin-5 business medicine.drug |
| Zdroj: | Scandinavian journal of rheumatology. 39(4) |
| ISSN: | 1502-7732 |
| Popis: | This case report demonstrates that interleukin (IL)-5 levels and eosinophil cationic protein (ECP) correlated well with disease activity of Churg-Strauss syndrome (CSS) in a patient receiving treatment with leucotriene receptor antagonist and inhaled corticosteroid. In addition, ECP was localized in the inflamed tissue. IL-5 levels may thus provide a clue to therapeutic efficacy in patients with CSS using leucotriene receptor antagonists and inhaled corticosteroid. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|